[
  {
    "id": "RES001",
    "evidenceId": "EVI001",
    "cancerType": "NSCLC",
    "gene": "EGFR",
    "alteration": "EGFR T790M",
    "subgroupLabel": "NSCLC + EGFR T790M",
    "lineOfTherapy": "2L",
    "drugName": "Osimertinib",
    "moa": "TKI",
    "metric": "PFS",
    "value": 10.1,
    "unit": "months",
    "resultNote": "median PFS; data cutoff: June 2016; AURA3 trial"
  },
  {
    "id": "RES002",
    "evidenceId": "EVI001",
    "cancerType": "NSCLC",
    "gene": "EGFR",
    "alteration": "EGFR T790M",
    "subgroupLabel": "NSCLC + EGFR T790M",
    "lineOfTherapy": "2L",
    "drugName": "Osimertinib",
    "moa": "TKI",
    "metric": "ORR",
    "value": 71,
    "unit": "%",
    "resultNote": "confirmed ORR by investigator assessment"
  },
  {
    "id": "RES003",
    "evidenceId": "EVI002",
    "cancerType": "NSCLC",
    "gene": "EGFR",
    "alteration": "EGFR_ex19del",
    "subgroupLabel": "NSCLC + EGFR exon19 del",
    "lineOfTherapy": "1L",
    "drugName": "Osimertinib",
    "moa": "TKI",
    "metric": "PFS",
    "value": 18.9,
    "unit": "months",
    "resultNote": "median PFS vs 10.2 months for gefitinib/erlotinib; FLAURA trial"
  },
  {
    "id": "RES004",
    "evidenceId": "EVI002",
    "cancerType": "NSCLC",
    "gene": "EGFR",
    "alteration": "EGFR_ex19del",
    "subgroupLabel": "NSCLC + EGFR exon19 del",
    "lineOfTherapy": "1L",
    "drugName": "Osimertinib",
    "moa": "TKI",
    "metric": "ORR",
    "value": 80,
    "unit": "%",
    "resultNote": "confirmed ORR by investigator; pooled ex19del and L858R"
  },
  {
    "id": "RES005",
    "evidenceId": "EVI002",
    "cancerType": "NSCLC",
    "gene": "EGFR",
    "alteration": "EGFR_L858R",
    "subgroupLabel": "NSCLC + EGFR L858R",
    "lineOfTherapy": "1L",
    "drugName": "Osimertinib",
    "moa": "TKI",
    "metric": "PFS",
    "value": 17.2,
    "unit": "months",
    "resultNote": "L858R subgroup; median PFS; FLAURA"
  },
  {
    "id": "RES006",
    "evidenceId": "EVI003",
    "cancerType": "NSCLC",
    "gene": "ALK",
    "alteration": "ALK_fusion",
    "subgroupLabel": "NSCLC + ALK fusion",
    "lineOfTherapy": "1L",
    "drugName": "Alectinib",
    "moa": "TKI",
    "metric": "PFS",
    "value": 34.8,
    "unit": "months",
    "resultNote": "median PFS vs 10.9 months for crizotinib; ALEX trial"
  },
  {
    "id": "RES007",
    "evidenceId": "EVI003",
    "cancerType": "NSCLC",
    "gene": "ALK",
    "alteration": "ALK_fusion",
    "subgroupLabel": "NSCLC + ALK fusion",
    "lineOfTherapy": "1L",
    "drugName": "Alectinib",
    "moa": "TKI",
    "metric": "ORR",
    "value": 82.9,
    "unit": "%",
    "resultNote": "confirmed ORR by investigator; treatment-naive"
  },
  {
    "id": "RES008",
    "evidenceId": "EVI004",
    "cancerType": "NSCLC",
    "gene": "ALK",
    "alteration": "ALK_fusion",
    "subgroupLabel": "NSCLC + ALK fusion",
    "lineOfTherapy": "3L+",
    "drugName": "Lorlatinib",
    "moa": "TKI",
    "metric": "ORR",
    "value": 42,
    "unit": "%",
    "resultNote": "intracranial ORR 63%; post-crizotinib + second-gen ALK-TKI"
  },
  {
    "id": "RES009",
    "evidenceId": "EVI004",
    "cancerType": "NSCLC",
    "gene": "ALK",
    "alteration": "ALK_fusion",
    "subgroupLabel": "NSCLC + ALK fusion",
    "lineOfTherapy": "3L+",
    "drugName": "Lorlatinib",
    "moa": "TKI",
    "metric": "PFS",
    "value": 6.9,
    "unit": "months",
    "resultNote": "median PFS; heavily pretreated population"
  },
  {
    "id": "RES010",
    "evidenceId": "EVI005",
    "cancerType": "NSCLC",
    "gene": "EGFR",
    "alteration": "EGFR_ex19del",
    "subgroupLabel": "NSCLC + EGFR exon19 del",
    "lineOfTherapy": "1L",
    "drugName": "Afatinib",
    "moa": "TKI",
    "metric": "PFS",
    "value": 11.0,
    "unit": "months",
    "resultNote": "vs 10.9 months for gefitinib; LUX-Lung 7"
  },
  {
    "id": "RES011",
    "evidenceId": "EVI005",
    "cancerType": "NSCLC",
    "gene": "EGFR",
    "alteration": "EGFR_ex19del",
    "subgroupLabel": "NSCLC + EGFR exon19 del",
    "lineOfTherapy": "1L",
    "drugName": "Afatinib",
    "moa": "TKI",
    "metric": "ORR",
    "value": 70,
    "unit": "%",
    "resultNote": "confirmed ORR by independent review"
  },
  {
    "id": "RES012",
    "evidenceId": "EVI007",
    "cancerType": "NSCLC",
    "gene": "EGFR",
    "alteration": "EGFR_ex19del",
    "subgroupLabel": "NSCLC + EGFR exon19 del",
    "lineOfTherapy": "2L",
    "drugName": "Investigational_Drug_X",
    "moa": "TKI",
    "metric": "ORR",
    "value": 34,
    "unit": "%",
    "resultNote": "T790M-negative resistance; preprint data; small N=127"
  },
  {
    "id": "RES013",
    "evidenceId": "EVI007",
    "cancerType": "NSCLC",
    "gene": "EGFR",
    "alteration": "EGFR_ex19del",
    "subgroupLabel": "NSCLC + EGFR exon19 del",
    "lineOfTherapy": "2L",
    "drugName": "Investigational_Drug_X",
    "moa": "TKI",
    "metric": "PFS",
    "value": 7.2,
    "unit": "months",
    "resultNote": "median PFS; retrospective analysis; T790M-negative"
  },
  {
    "id": "RES014",
    "evidenceId": "EVI008",
    "cancerType": "NSCLC",
    "gene": "ALK",
    "alteration": "ALK_fusion",
    "subgroupLabel": "NSCLC + ALK fusion",
    "lineOfTherapy": "1L",
    "drugName": "Brigatinib",
    "moa": "TKI",
    "metric": "PFS",
    "value": 24.0,
    "unit": "months",
    "resultNote": "median PFS vs 11.0 months for crizotinib; ALTA-1L"
  },
  {
    "id": "RES015",
    "evidenceId": "EVI008",
    "cancerType": "NSCLC",
    "gene": "ALK",
    "alteration": "ALK_fusion",
    "subgroupLabel": "NSCLC + ALK fusion",
    "lineOfTherapy": "1L",
    "drugName": "Brigatinib",
    "moa": "TKI",
    "metric": "ORR",
    "value": 71,
    "unit": "%",
    "resultNote": "confirmed ORR by IRC assessment"
  }
]
